Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Azithromycin and bronchopulmonary infections]

P Leophonte1

  • 1Service de Pneumologie, Hôpital Rangueil, Toulouse, France.

Pathologie-Biologie
|June 1, 1995
PubMed
Summary

Azithromycin effectively treats community-acquired lower respiratory tract infections by achieving high concentrations in lung tissue. It shows superior activity against key pathogens like Streptococcus pneumoniae and Haemophilus influenzae.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Home telemonitoring of lung-transplanted patients: A feasibility study].

Revue des maladies respiratoires·2014
Same author

[Evaluation of a manual CPAP home telemonitoring device to an automatic one].

Revue des maladies respiratoires·2014
Same author

[Telemedicine and lung transplanted patients: A feasibility study].

Revue des maladies respiratoires·2014
Same author

[Impact of facial versus nose mask on the length of use of CPAP in patients with Sleep Apnea Syndrome?].

Revue des maladies respiratoires·2013
Same author

[Education of patients with sleep apnea syndrome: Feasibility of a phone coaching procedure. Phone-coaching and SAS].

Revue des maladies respiratoires·2012
Same author

[Home telemonitoring of CPAP: a feasibility study].

Revue des maladies respiratoires·2012

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Azithromycin, an azalide macrolide, is used for community-acquired lower respiratory tract infections.
  • Common pathogens include H. influenzae, S. pneumoniae, M. catarrhalis, C. pneumoniae, and M. pneumoniae.

Purpose of the Study:

  • To evaluate azithromycin's efficacy in treating lower respiratory tract infections.
  • To assess its pharmacokinetic profile and activity against common respiratory pathogens.

Main Methods:

  • Analysis of azithromycin's Minimum Inhibitory Concentrations (MIC90) against various bacteria.
  • Pharmacokinetic studies measuring drug concentrations in pulmonary tissues.
  • In vivo animal models and clinical studies to confirm efficacy.
  • Comparative analysis against other macrolides.

Main Results:

  • Azithromycin exhibits low to slightly elevated MIC90 values against common respiratory pathogens.
  • High and persistent azithromycin concentrations are achieved in lung tissues after oral administration.
  • Azithromycin concentrates in polymorphonuclear leukocytes, enhancing delivery to infection sites.
  • Demonstrated superior activity compared to other macrolides against S. pneumoniae and H. influenzae in experimental models.

Conclusions:

  • Azithromycin's pharmacokinetic properties and potent activity support its use in respiratory tract infections.
  • Its ability to concentrate in lung tissue and leukocytes contributes to clinical efficacy.
  • Consideration of macrolide resistance in S. pneumoniae is important for treatment strategies.

Related Experiment Videos